KHK7791 + Placebp
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hyperphosphatemia
Conditions
Hyperphosphatemia
Trial Timeline
Apr 29, 2019 → Dec 3, 2019
NCT ID
NCT03864445About KHK7791 + Placebp
KHK7791 + Placebp is a phase 2 stage product being developed by Kyowa Kirin for Hyperphosphatemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03864445. Target conditions include Hyperphosphatemia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03864445 | Phase 2 | Completed |
Competing Products
20 competing products in Hyperphosphatemia